Viridian Therapeutics, Inc.
VRDN
$16.86
-$0.34-1.98%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 12.84% | -247.86% | 65.65% | -15.90% | -9.01% |
| Total Depreciation and Amortization | 131.84% | -162.30% | 439.82% | -3.42% | 117.28% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -58.32% | 61.06% | 3.43% | 17.34% | 20.98% |
| Change in Net Operating Assets | -126.29% | 234.84% | -480.26% | 214.51% | -3,111.96% |
| Cash from Operations | -403.72% | 71.93% | -12.26% | 18.65% | -26.35% |
| Capital Expenditure | 90.42% | -88.98% | -202.38% | 51.16% | 24.56% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 122.79% | -368.76% | 66.58% | -24.35% | 259.47% |
| Cash from Investing | 122.76% | -369.22% | 66.51% | -24.33% | 259.04% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -98.16% | 3,024.33% | 1,348.43% | -91.89% | -74.43% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 15,074.16% | -- | 100.00% | 84.20% |
| Cash from Financing | -98.43% | 3,638.68% | 1,321.07% | -91.71% | -74.07% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -184.32% | -18.32% | 4,618.03% | -93.33% | 116.50% |